Evidence map›Paper›PMID 41736438›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026

Title-effectiveness and safety of Danshen injection for acute kidney injury in primary nephrotic syndrome.

Shi Yanling, Zhu Jianfen, Chen Bo, You Xiaohan, Chen Xinxin, Chen Tianxin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shi YanlingDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Zhu JianfenDepartment of Internal Medicine Nursing and Endoscopy Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Chen BoDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
You XiaohanDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Chen XinxinDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Chen TianxinDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.

Funding

Basic Research Project of Wenzhou Science and Technology Bureau: the Mechanism of Hypoxia Induicible Factor-1 alpha Down-regulating Angiotensin-converting Enzyme 2 in Proximal Renal Tubular Epithelial Cells Leading to Brush Border Shedding in Early Acute Kidney Injury Induced by Sepsis Y20240071Key Project of Science and Technology Program Co-constructed by the Science and Technology Department of the National Administration of Traditional Chinese Medicine of China and Administration of Traditional Chinese Medicine of Zhejiang Province: A Study on the Efficacy and Safety of Danshen () in Treating Acute Kidney Injury in Patients with Primary Nephrotic Syndrome GZY-ZJ-KJ-23085
6 · The paper itself

Abstract

objectiveTo assess the clinical effectiveness and safety of Danshen injection following immunosuppressive therapy in primary nephrotic syndrome (PNS) with acute kidney injury (AKI) patients.

methodsPNS with AKI patients selected from nephrotic syndrome inpatients between 2012 and 2022 were divided into two groups according to the treatment regimen: the DS group who were treated with the Danshen injection and the SC group who received supportive care. Propensity score matching was used to balance the confounding factors between the two groups. The outcomes were complete and partial renal function recovery for effectiveness analysis and severe bleeding events for safety analysis. Kaplan-Meier curves and log-rank tests were used to compare cumulative recovery rates. Outcome risks were assessed using Cox proportional hazard regression models.

resultsThe study enrolled 441 patients with PNS and AKI from a population of 3873 inpatients with nephrotic syndrome. Among them, 95 received Danshen injection, and 346 received supportive care. After propensity score matching, 95 patients in the DS group and 285 patients in the SC group were analyzed. No significant difference was observed in the complete recovery rate for the DS group

conclusionIn this real-world retrospective study of PNS with AKI patients, Danshen injection following immunosuppressive therapy and prophylactic anticoagulation with low molecular heparin significantly increased 6-month partial renal function recovery and had a safety profile. Further randomized clinical trials are warranted to confirm the benefit of Danshen (

Indexed as

Acute Kidney InjuryDrugs, Chinese HerbalNephrotic SyndromeSalvia miltiorrhizaAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung Adultdan-shen root extractDrugs, Chinese Herbalacute kidney injuryDanshen ()Danshen injectionnephrotic syndrome

Identifiers

PMID41736438
PMCPMC12884491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.